Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603275 · ClinicalTrials.gov registry record
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry
A clinical trial, sponsored by Bayer.
- Terminated
- Registry status
- 3
- Enrollment target
NCT03603275: Clinical Trial study, sponsored by Bayer.
NCT03603275 is a clinical trial that was terminated before completion, run by Bayer. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603275 was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This US study aims to assess hemophilia A patient characteristics and reasons for switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A patients who have switched from an existing therapy to Kovaltry or Jivi. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.
Primary Outcome
Data from consenting patients will be collected by ATHN
Interventions
- DRUG New FVIII products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-06 |
| Est. Completion | 2020-05-14 |
Why NCT03603275 stopped before completion
NCT03603275 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which New FVIII products is the first listed.
NCT03603275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03603275 about?
NCT03603275 is a clinical study titled "Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry". This US study aims to assess hemophilia A patient characteristics and reasons for switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A patients who have switched from an existing therapy to Kovaltry or Jivi. In doing so, re...
What is the current status of trial NCT03603275?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2018-08-06. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT03603275?
The interventions under investigation include: New FVIII products (DRUG).
Who is sponsoring clinical trial NCT03603275?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI